extract: 2025-12-01-who-glp1-global-guidelines-obesity

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -41,6 +41,12 @@ MA plans' near-universal prior authorization creates administrative friction tha
 
 MASH/NASH is projected to become the leading cause of liver transplantation. GLP-1s now demonstrate efficacy across three major organ systems (cardiovascular, renal, hepatic), which strengthens the multi-indication economic case for chronic use. The 62.9% MASH resolution rate suggests GLP-1s could prevent progression to late-stage liver disease and transplantation, though the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades and falls outside typical budget scoring windows.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO issued conditional recommendations (not full endorsements) for GLP-1s in obesity treatment, acknowledging 'limited long-term evidence' and requiring countries to 'consider local cost-effectiveness, budget impact, and ethical implications.' The conditional framing and emphasis on budget impact analysis suggests even the global health authority recognizes the chronic use economics remain unproven at scale, particularly for low/middle-income countries.
+
 ---
 
 Relevant Notes:

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -41,6 +41,12 @@ The Commonwealth Fund's 2024 Mirror Mirror international comparison provides the
 
 The NHS paradox—ranking 3rd overall while having catastrophic specialty access—provides supporting evidence that medical care's contribution to health outcomes is limited. A system can have multi-year waits for specialty procedures yet still rank highly in overall health system performance because primary care, equity, and universal coverage (which address behavioral and social factors) matter more than specialty delivery speed for population health outcomes.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-12-01-who-glp1-global-guidelines-obesity]] | Added: 2026-03-16*
+
+WHO's three-pillar framework for GLP-1 implementation explicitly positions medication as one component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies. The framework states obesity is a 'societal challenge requiring multisectoral action — not just individual medical treatment,' directly supporting the view that medical intervention alone cannot address health outcomes dominated by behavioral and social factors.
+
 ---
 
 Relevant Notes:

inbox/archive/2025-12-01-who-glp1-global-guidelines-obesity.md

@@ -7,9 +7,13 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: policy
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, WHO, global-health, obesity, guidelines, equity]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,10 @@ WHO issued conditional recommendations for GLP-1 medicines in obesity treatment
 PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 WHY ARCHIVED: WHO's three-pillar framework challenges the pharmacological solution narrative and supports the view that GLP-1s are most effective when embedded in structural prevention infrastructure
 EXTRACTION HINT: The WHO position supports the BALANCE model's design but questions whether pharmaceutical solutions alone can address the obesity epidemic
+
+
+## Key Facts
+- WHO issued global guideline on GLP-1 medicines for obesity treatment on December 1, 2025
+- WHO recommendations are conditional, not full endorsements
+- WHO framework has three pillars: population-level policies, protecting high-risk individuals, and person-centered care
+- WHO emphasizes GLP-1s must be part of comprehensive approach including diet, physical activity, and professional support